NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($3.62) by $0.37. The biopharmaceutical company earned $1.96 million during the quarter, compared to analyst estimates of $3.76 million. SAGE Therapeutics had a negative return on equity of 56.63% and a negative net margin of 9,904.45%. The company's revenue for the quarter was up 617.9% on a year-over-year basis. During the same period in the previous year, the company earned ($3.38) EPS. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for SAGE Therapeutics.

20 brokerages have issued 12 month target prices for SAGE Therapeutics' shares. Their forecasts range from $50.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $112.22 in the next twelve months. This suggests a possible upside of 138.8% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Media stories about SAGE stock have been trending very negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. SAGE Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM) and GW Pharmaceuticals PLC- (GWPH).

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Capital International Investors (7.36%), Janus Henderson Group PLC (4.66%), State Street Corp (3.20%), Victory Capital Management Inc. (2.05%) and Franklin Resources Inc. (1.69%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Franklin Resources Inc., Casdin Capital LLC, Fiera Capital Corp, New York State Common Retirement Fund, Tocqueville Asset Management L.P. and Oak Ridge Investments LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Victory Capital Management Inc., Janus Henderson Group PLC, Boxer Capital LLC, Victory Capital Management Inc., EcoR1 Capital LLC, Capital International Investors and Zevenbergen Capital Investments LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $47.00.

SAGE Therapeutics has a market capitalization of $2.44 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]